Literature DB >> 20007403

Evaluation of risk factors for coinfection or cocolonization with vancomycin-resistant enterococcus and methicillin-resistant Staphylococcus aureus.

Katherine Reyes1, Rushdah Malik, Carol Moore, Susan Donabedian, Mary Perri, Laura Johnson, Marcus Zervos.   

Abstract

We retrospectively evaluated 410 patients with coinfection or cocolonization due to vancomycin-resistant (VR) enterococcus (VRE) and methicillin-resistant Staphylococcus aureus (MRSA). The prevalence rate was 19.8%. Risk factors included isolation of VR Enterococcus faecalis and use of linezolid or clindamycin. Inc18-like vanA plasmids were found in 7% of VR E. faecalis isolates and none of the VR E. faecium isolates.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 20007403      PMCID： PMC2815608          DOI： 10.1128/JCM.02381-08

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  16 in total

1.  Co-infection or co-colonization with vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus in a network of community hospitals.

Authors:  Jay R McDonald; John J Engemann; Keith S Kaye; Daniel J Sexton
Journal:  Infect Control Hosp Epidemiol       Date:  2004-08       Impact factor: 3.254

2.  Seeking vancomycin resistant Staphylococcus aureus among patients with vancomycin-resistant enterococci.

Authors:  D Franchi; M W Climo; A H Wong; M B Edmond; R P Wenzel
Journal:  Clin Infect Dis       Date:  1999-12       Impact factor: 9.079

Review 3.  Vancomycin-resistant staphylococci and enterococci: epidemiology and control.

Authors:  Fred C Tenover; L Clifford McDonald
Journal:  Curr Opin Infect Dis       Date:  2005-08       Impact factor: 4.915

4.  Plasmid content of a vancomycin-resistant Enterococcus faecalis isolate from a patient also colonized by Staphylococcus aureus with a VanA phenotype.

Authors:  Susan E Flannagan; Joseph W Chow; Susan M Donabedian; William J Brown; Mary B Perri; Marcus J Zervos; Yoshiyuki Ozawa; Don B Clewell
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

5.  Occurrence of co-colonization or co-infection with vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus in a medical intensive care unit.

Authors:  David K Warren; Anand Nitin; Cheri Hill; Victoria J Fraser; Marin H Kollef
Journal:  Infect Control Hosp Epidemiol       Date:  2004-02       Impact factor: 3.254

6.  NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007.

Authors:  Alicia I Hidron; Jonathan R Edwards; Jean Patel; Teresa C Horan; Dawn M Sievert; Daniel A Pollock; Scott K Fridkin
Journal:  Infect Control Hosp Epidemiol       Date:  2008-11       Impact factor: 3.254

7.  Completed sequence of plasmid pIP501 and origin of spontaneous deletion derivatives.

Authors:  J K Thompson; M A Collins
Journal:  Plasmid       Date:  2003-07       Impact factor: 3.466

8.  Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus.

Authors:  W C Noble; Z Virani; R G Cree
Journal:  FEMS Microbiol Lett       Date:  1992-06-01       Impact factor: 2.742

9.  Recommendations for preventing the spread of vancomycin resistance. Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC).

Authors: 
Journal:  MMWR Recomm Rep       Date:  1995-09-22

10.  Genetic analysis of a high-level vancomycin-resistant isolate of Staphylococcus aureus.

Authors:  Linda M Weigel; Don B Clewell; Steven R Gill; Nancye C Clark; Linda K McDougal; Susan E Flannagan; James F Kolonay; Jyoti Shetty; George E Killgore; Fred C Tenover
Journal:  Science       Date:  2003-11-28       Impact factor: 47.728
View more
  10 in total

1.  Predictors of methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci co-colonization among nursing facility patients.

Authors:  Kevin Heinze; Mohammed Kabeto; Emily Toth Martin; Marco Cassone; Liam Hicks; Lona Mody
Journal:  Am J Infect Control       Date:  2018-11-28       Impact factor: 2.918

2.  Increase of patients co-colonised or co-infected with methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium or extended-spectrum β-lactamase-producing Enterobacteriaceae.

Authors:  E Meyer; R Ziegler; F Mattner; F Schwab; P Gastmeier; M Martin
Journal:  Infection       Date:  2011-06-28       Impact factor: 3.553

Review 3.  Horizontal gene transfer and the genomics of enterococcal antibiotic resistance.

Authors:  Kelli L Palmer; Veronica N Kos; Michael S Gilmore
Journal:  Curr Opin Microbiol       Date:  2010-09-15       Impact factor: 7.934

4.  Wounds, functional disability, and indwelling devices are associated with cocolonization by methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci in southeast Michigan.

Authors:  Erika L Flannery; Linda Wang; Sebastian Zöllner; Betsy Foxman; Harry L T Mobley; Lona Mody
Journal:  Clin Infect Dis       Date:  2011-12       Impact factor: 9.079

5.  Endocarditis caused by resistant enterococcus: an overview.

Authors:  Katherine Reyes; Marcus Zervos
Journal:  Curr Infect Dis Rep       Date:  2013-08       Impact factor: 3.725

6.  Comparison of the clinical characteristics and outcomes associated with vancomycin-resistant Enterococcus faecalis and vancomycin-resistant E. faecium bacteremia.

Authors:  Kayoko Hayakawa; Dror Marchaim; Emily T Martin; Namita Tiwari; Adnan Yousuf; Bharath Sunkara; Harish Pulluru; Harikrishna Kotra; Asma Hasan; Suchitha Bheemreddy; Puja Sheth; Dae-Won Lee; Srinivasa Kamatam; Pradeep Bathina; Priyanka Nanjireddy; Indu K Chalana; Satyam Patel; Sarwan Kumar; Amit Vahia; Kimberly Ku; Victoria Yee; Jessie Swan; Jason M Pogue; Paul R Lephart; Michael J Rybak; Keith S Kaye
Journal:  Antimicrob Agents Chemother       Date:  2012-02-21       Impact factor: 5.191

7.  Epidemiology of vancomycin-resistant Enterococcus faecalis: a case-case-control study.

Authors:  Kayoko Hayakawa; Dror Marchaim; Mohan Palla; Uma Mahesh Gudur; Harish Pulluru; Pradeep Bathina; Khaled Alshabani; Aditya Govindavarjhulla; Ashwini Mallad; Deepika Reddy Abbadi; Deepti Chowdary; Hari Kakarlapudi; Harish Guddati; Manoj Das; Naveen Kannekanti; Praveen Vemuri; Rajiv Doddamani; Venkat Ram Rakesh Mundra; Raviteja Reddy Guddeti; Rohan Policherla; Sarika Bai; Sharan Lohithaswa; Shiva Prasad Shashidharan; Sowmya Chidurala; Sreelatha Diviti; Krishna Sukayogula; Melwin Joseph; Jason M Pogue; Paul R Lephart; Emily T Martin; Michael J Rybak; Keith S Kaye
Journal:  Antimicrob Agents Chemother       Date:  2012-10-15       Impact factor: 5.191

8.  Independent risk factors for the co-colonization of vancomycin-resistant Enterococcus faecalis and methicillin-resistant Staphylococcus aureus in the region most endemic for vancomycin-resistant Staphylococcus aureus isolation.

Authors:  K Hayakawa; D Marchaim; P Bathina; E T Martin; J M Pogue; B Sunkara; S Kamatam; K Ho; L B Willis; M Ajamoughli; D Patel; A Khan; K P Lee; U Suhrawardy; K K Jagadeesh; S M L Reddy; M Levine; F Ahmed; A M Omotola; M Mustapha; J A Moshos; M J Rybak; K S Kaye
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-01-26       Impact factor: 3.267

9.  Determining the clinical significance of co-colonization of vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus in the intestinal tracts of patients in intensive care units: a case-control study.

Authors:  Young Kyung Yoon; Min Jung Lee; Yongguk Ju; Sung Eun Lee; Kyung Sook Yang; Jang Wook Sohn; Min Ja Kim
Journal:  Ann Clin Microbiol Antimicrob       Date:  2019-10-10       Impact factor: 3.944

10.  Synergistic Microbicidal Effect of Auranofin and Antibiotics Against Planktonic and Biofilm-Encased S. aureus and E. faecalis.

Authors:  Pengfei She; Linying Zhou; Shijia Li; Yiqing Liu; Lanlan Xu; Lihua Chen; Zhen Luo; Yong Wu
Journal:  Front Microbiol       Date:  2019-10-24       Impact factor: 5.640
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.